BAJAJ BROKING
Biocon Biologics has partnered with Civica to provide affordable insulin aspart in the US. The agreement ensures a steady supply of the diabetes drug, enhancing accessibility. Biocon share price rose 2.60% to ₹333.10 following the announcement.
Biocon Biologics Ltd, a subsidiary of Biocon Ltd, has entered into a strategic partnership with Civica Inc, a US-based non-profit pharmaceutical company, to enhance the affordability and accessibility of insulin aspart in the United States. The agreement ensures Biocon Biologics will supply the insulin aspart drug substance, while Civica will handle production and commercialisation in the US.
This collaboration aims to address the growing demand for cost-effective diabetes treatment in the country. Insulin aspart is a rapid-acting insulin analogue commonly used to manage blood sugar levels in diabetic patients. The partnership is expected to bring financial relief to thousands of Americans who rely on insulin therapy.
Also read: Brigade Enterprises Unveils Brigade Altius in Chennai with ₹1,700 Crore Potential
Biocon Biologics and Civica Inc collaborate to provide affordable insulin aspart in the US.
Biocon Biologics will supply the drug substance, while Civica will handle production and distribution.
The insulin aspart drug product will be manufactured at Civica’s Virginia facility.
This partnership complements Biocon Biologics' own insulin aspart drug, currently under US FDA review.
Biocon share price surged by 2.60% to ₹333.10 following the announcement.
Also read: TCS Expands Partnership with Northern Trust to Modernise Securities Services
Under the terms of the agreement, Biocon Biologics will supply the drug substance for insulin aspart, which Civica will use to manufacture the final product at its facility in Petersburg, Virginia. This initiative will allow Civica to distribute affordable insulin to US patients, reducing the financial burden associated with diabetes treatment. Unlike many other pharmaceutical deals, this partnership does not involve a technology transfer, making it a straightforward supply and production agreement.
Aspect | Details |
Companies Involved | Biocon Biologics Ltd, Civica Inc |
Drug Supplied | Insulin Aspart (Rapid-Acting Insulin) |
Manufacturing Location | Petersburg, Virginia, US |
Commercialisation | Civica Inc |
Additional Developments | Biocon Biologics’ insulin aspart under US FDA review |
Following the announcement, Biocon share price witnessed a 2.60% increase, closing at ₹333.10 on the BSE. This reflects investor confidence in the company's global expansion efforts and commitment to providing affordable healthcare solutions. The stock’s positive movement suggests that the market views this partnership as a strong step toward capturing a larger share of the insulin market in the US.
Biocon Biologics' collaboration with Civica marks a significant move in making insulin more affordable in the US. This partnership reinforces Biocon's position in the global diabetes care segment while providing financial relief to insulin-dependent patients. As the market awaits regulatory approvals for Biocon Biologics’ own insulin aspart drug, investors will closely monitor further developments in the company's expansion strategy. The growing demand for cost-effective diabetes treatment could drive further interest in Biocon share price in the coming months.
Also read: BEL Secures ₹577 Crore in New Orders; FY25 Order Book Reaches ₹13,724 Crore
Do you have a trading account app or demat account app?
You can open an account with Bajaj Broking in minutes.
Download the Bajaj Broking app now from Play Store or App Store.
Disclaimer: Investments in the securities market are subject to market risk, read all related documents carefully before investing.
This content is for educational purposes only. Securities quoted are exemplary and not recommendatory.
For All Disclaimers Click Here: https://www.bajajbroking.in/disclaimer
Share this article:
Disclaimer :
The information on this website is provided on "AS IS" basis. Bajaj Broking (BFSL) does not warrant the accuracy of the information given herein, either expressly or impliedly, for any particular purpose and expressly disclaims any warranties of merchantability or suitability for any particular purpose. While BFSL strives to ensure accuracy, it does not guarantee the completeness, reliability, or timeliness of the information. Users are advised to independently verify details and stay updated with any changes.
The information provided on this website is for general informational purposes only and is subject to change without prior notice. BFSL shall not be responsible for any consequences arising from reliance on the information provided herein and shall not be held responsible for all or any actions that may subsequently result in any loss, damage and or liability. Interest rates, fees, and charges etc., are revised from time to time, for the latest details please refer to our Pricing page.
Neither the information, nor any opinion contained in this website constitutes a solicitation or offer by BFSL or its affiliates to buy or sell any securities, futures, options or other financial instruments or provide any investment advice or service.
BFSL is acting as distributor for non-broking products/ services such as IPO, Mutual Fund, Insurance, PMS, and NPS. These are not Exchange Traded Products. For more details on risk factors, terms and conditions please read the sales brochure carefully before investing.
Investments in the securities market are subject to market risk, read all related documents carefully before investing. This content is for educational purposes only. Securities quoted are exemplary and not recommendatory.
For more disclaimer, check here : https://www.bajajbroking.in/disclaimer
Level up your stock market experience: Download the Bajaj Broking App for effortless investing and trading